Physician profile
Mary Eng
NPI 1710940879
$5,815.41
in general payments reported to CMS, 2019-2025
24 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $228 · 2021: $770 · 2022: $1,528 · 2023: $681 · 2024: $908 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $1,041.72 | 2019-2025 | Envarsus |
| Coloplast Corp | $637.30 | 2021-2024 | Isiris Astent Removal Device, Porges Coloplast |
| Pacira Pharmaceuticals Incorporated | $426.87 | 2020-2022 | |
| Vifor Pharma, INC. | $351.55 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $338.37 | 2022-2025 | Tarpeyo |
| Tela Bio, INC. | $286.00 | 2022 | |
| Astellas Pharma US INC | $248.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $241.84 | 2021-2025 | Terlivaz, Acthar |
| Scpharmaceuticals INC. | $238.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $218.93 | 2019 | |
| Travere Therapeutics, INC. | $217.96 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.27 | 2021-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $133.01 | 2023-2024 | Prevymis |
| Takeda Pharmaceuticals U.S.A., INC. | $130.00 | 2024 | Livtencity |
| Alcresta Therapeutics, INC. | $124.53 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $122.41 | 2025 | |
| Gilead Sciences, INC. | $122.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $121.46 | 2023 | |
| Baxter Healthcare | $121.24 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.70 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $119.70 | 2024 | Farxiga |
| Genzyme Corporation | $113.40 | 2024 | |
| Davol INC. | $103.45 | 2023 | Phasix Mesh |
| Shionogi INC | $101.73 | 2025 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.